Video education to improve genetic testing for hereditary cancers
Video Education With Result Dependent dIsclosure
This study is testing a new video education tool to see if it helps people understand genetic testing for hereditary cancers better than regular counseling.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 1020 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Dana-Farber Cancer Institute Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT05225428 on ClinicalTrials.gov |
What this trial studies
This study aims to enhance the accessibility of the Video Education with Result Dependent Disclosure (VERDI) model, which serves as a pre-genetic testing educational tool. It consists of two parts: a qualitative assessment involving a brief educational video followed by interviews with participants, and a randomized controlled trial comparing the VERDI model to standard genetic counseling in a larger cohort. The goal is to refine the VERDI model to better serve diverse patient populations at risk for hereditary cancers.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 18 and older with a current or prior diagnosis of specific cancers and who identify as Black or Latinx.
Not a fit: Patients who have previously undergone cancer genetic testing or have active hematologic malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve patient understanding and accessibility to genetic testing for hereditary cancers.
How similar studies have performed: Other studies have shown promise in using video education for genetic counseling, but this specific approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Current or prior diagnosis of breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, colorectal cancer, renal cancer, melanoma, or sarcoma * Ability to understand spoken or written English or Spanish in a healthcare context * Ability to understand and the willingness to sign a written informed consent document * Black or Latinx (qualitative assessment study only) Exclusion Criteria: * Prior cancer genetic testing * Prior germline genetic testing * Active hematologic malignancy (e.g. chronic lymphocytic leukemia) * Currently pregnant * Currently incarcerated
Where this trial is running
Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts, United States (Recruiting)
Study contacts
- Principal investigator: Huma Q. Rana, MD., MPH — Dana-Farber Cancer Institute
- Study coordinator: Huma Q. Rana, MD. MPH
- Email: humaQ_rana@dfci.harvard.edu
- Phone: 617) 632-6292
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.